Today, Athersys announced that the agreement between the company and Chugai to develop and commercialize MultiStem in Japan has ended following the failure of negotiations to modify the financial terms of the agreement and to decide on a development strategy. However, Athersys also announced that it has already signed a letter of intent with another Japanese company to develop and commercialize MultiStem in Japan in ischemic stroke and other areas.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
One door closes, another one opens
Today, Athersys announced that the agreement between the company and Chugai to develop and commercialize MultiStem in Japan has ended following the failure of negotiations to modify the financial terms of the agreement and to decide on a development strategy. However, Athersys also announced that it has already signed a letter of intent with another Japanese company to develop and commercialize MultiStem in Japan in ischemic stroke and other areas.